The Commission on Human Medicines (CHM) has endorsed changes to isotretinoin prescribing guidance. In addition, CHM is seeking further information from dermatology services who prescribe isotretinoin to inform any future changes to current risk minimisation measures.
Similar Posts
Trinity Biotech Premier Hb9210™ HbA1c Analyser: Risk of Positive Bias and Updates to Instructions for Use (IFU), including use as a diagnostic aid in diabetes mellitus (DSI/2025/003)
The MHRA has received reports describing a positive bias in HbA1c results delivered by the Trinity Biotech Premier Hb9210 HbA1c analyser, which has resulted in patients being incorrectly diagnosed as pre-diabetic or diabetic.
Clinical trials for medicines: manage your authorisation, report safety issues
Change your protocol, update your authorisation, report safety issues, submit safety updates and complete your end-of-trial study report.
MHRA issues new guidance for people using mental health apps and technologies
New online resources will help the public, parents, carers and health, social care and education professionals understand what safe, effective digital mental health technologies look like in practice.
Guidance: MHRA guidance on the use of real-world data in clinical studies to support regulatory decisions
Points to consider when using real-world data in clinical studies
Side effects from drug interactions to be predicted by AI before reaching patients
The MHRA leads three new government-backed projects using AI-driven approaches to make medicines safer and bring treatments to patients more quickly.
Clinical trials for medicines: labelling
Guidance on labelling for medicinal products used in clinical trials.